PriceTargets.com logo

Atossa Genetics - ATOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.17
  • Forecasted Upside: 609.22%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$0.87 As of 07/17/2025 05:00 PM ET
▼ -0.0221 (-2.48%)

This chart shows the closing price for ATOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atossa Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATOS

Analyst Price Target is $6.17
▲ +609.22% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Atossa Genetics in the last 3 months. The average price target is $6.17, with a high forecast of $7.50 and a low forecast of $4.00. The average price target represents a 609.22% upside from the last price of $0.87.

This chart shows the closing price for ATOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Atossa Genetics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2025

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/6/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$7.25 ➝ $7.50
6/5/2025Craig HallumUpgradeStrong-Buy$4.00
4/21/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$7.00 ➝ $7.25
3/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
1/30/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
12/9/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.50 ➝ $7.00
11/13/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
9/11/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.25 ➝ $6.50
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
6/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/6/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.00 ➝ $6.25
5/14/2024Cantor FitzgeraldReiterated RatingOverweight
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $6.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00
2/12/2024HC WainwrightReiterated RatingBuy$4.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
9/8/2023Cantor FitzgeraldInitiated CoverageOverweight$5.00
11/16/2022Ascendiant Capital MarketsLower Target$6.00
8/22/2022Ascendiant Capital MarketsLower Target$7.00
9/18/2020Maxim GroupReiterated RatingBuy$8.00
9/17/2020Ascendiant Capital MarketsInitiated CoverageBuy$7.00
7/31/2020Maxim GroupReiterated RatingBuy$8.00
(Data available from 7/18/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2025
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/18/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
3/20/2025
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
4/19/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/19/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Atossa Genetics logo
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $0.87
Low: $0.87
High: $0.93

50 Day Range

MA: $0.87
Low: $0.76
High: $1.03

52 Week Range

Now: $0.87
Low: $0.55
High: $1.66

Volume

948,862 shs

Average Volume

750,129 shs

Market Capitalization

$112.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Atossa Genetics?

The following Wall Street research analysts have issued stock ratings on Atossa Genetics in the last year: Ascendiant Capital Markets, Craig Hallum, HC Wainwright, and Wall Street Zen.
View the latest analyst ratings for ATOS.

What is the current price target for Atossa Genetics?

0 Wall Street analysts have set twelve-month price targets for Atossa Genetics in the last year. Their average twelve-month price target is $6.17, suggesting a possible upside of 609.2%. Ascendiant Capital Markets has the highest price target set, predicting ATOS will reach $7.50 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $4.00 for Atossa Genetics in the next year.
View the latest price targets for ATOS.

What is the current consensus analyst rating for Atossa Genetics?

Atossa Genetics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATOS will outperform the market and that investors should add to their positions of Atossa Genetics.
View the latest ratings for ATOS.

What other companies compete with Atossa Genetics?

Other companies that are similar to Atossa Genetics include Cullinan Therapeutics, MBX Biosciences, Rezolute, Kamada and Terns Pharmaceuticals. Learn More about companies similar to Atossa Genetics.

How do I contact Atossa Genetics' investor relations team?

Atossa Genetics' physical mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company's listed phone number is (206) 588-0256 and its investor relations email address is [email protected]. The official website for Atossa Genetics is atossatherapeutics.com. Learn More about contacing Atossa Genetics investor relations.